Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

The company's fact sheet can be viewed here.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss receiving imminent clearance from the FDA as well as the projected commencement dates for our upcoming clinical trials. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents m
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , ... July 03, 2015 ... ... providing industry-leading products for use in applications such as animal waste reduction, ... treatment plants and restaurant kitchen settings, announced today that it will be ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... ... 03, 2015 , ... The Alexander Group, a 30-year old, ... alike-- typically known for its consummate professionalism-- embarks each year in a whacky ... from their day jobs. , "Our motto has always been work hard play ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is expected to ... The bioscience market is expected to grow at the highest CAGR of 8.46%; its ... in the research labs and academic institutions for root cause analysis of failure. The ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... in Exchange, for Senior Subordinated and Subordinated Notes due 2008, ... ... Feb. 13 Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq: CTIC ... its outstanding 5.75%,Convertible Senior Subordinated Notes due 2008 (the "Senior Subordinated,Notes") and ...
... Recover Investments in Dedicated Assets -, LIONVILLE, ... WST ) today announced that it has ... the manufacture and,assembly of components for the Exubera(R) ... in October 2007 following Pfizer,Inc.,s decision to discontinue ...
... Feb. 13 Verenium,Corporation (Nasdaq: VRNM ), ... pioneer in the development of high-performance specialty,enzymes, announced ... President and Chief Financial Officer, will present at ... The presentation is,scheduled to begin at 10:00 a.m. ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008 2West Concludes Agreement with Nektar 2Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 2Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 3
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/15/2015)... June 15, 2015 A new report ... reveals the majority of US consumers using mobile banking applications ... such as fingerprint and voiceprint, instead of having to prove ... to Telstra,s " Mobile Identity   -   The Fusion ... with smartphones now the primary channel used by Gen X ...
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... and Interventional Radiology"an essential resource and the first offering ... armis now available. Also available is the companion "Patient ... Written by top experts in their areas of specialty, ... or in training, for certification or recertification or for ...
... In a lecture he delivered in 1906, the German ... as shorthand for a highly targeted medical treatment. Magic ... that only silver bullets can kill supernatural creatures, remain the ... scientists at Washington University in St. Louis is currently working ...
... New findings that shed light on how genetic damage ... of the rare muscle-wasting disease, nemaline myopathy, are reported ... Professor Laura Machesky and colleagues from the CRUK Beatson ... muscle cells that displayed mutations of the ACTA1 gene ...
Cached Biology News:Society of Interventional Radiology Press offers new edition of patient care resource 2A golden bullet for cancer 2A golden bullet for cancer 3A golden bullet for cancer 4A golden bullet for cancer 5New clues about the basis of muscle wasting disease 2
...
EoProbe Eosinophil Staining Kit, 1 Kit...
... kit contains the basic components required for ... natural and recombinant rat L-Selectin in cell ... contains sufficient materials to run ELISAs on ... following conditions are met: The ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: